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Abstract 1 
 2 
New therapeutic strategies targeting influenza are actively sought due to limitations in current 3 
drugs available. Host-directed therapy is an emerging concept to target host functions 4 
involved in pathogen life cycles and/or pathogenesis, rather than pathogen components 5 
themselves. From this perspective, we focused on an essential host partner of influenza 6 
viruses, the RED-SMU1 splicing complex. Here we identified two synthetic molecules 7 
targeting an a-helix-groove interface essential for RED-SMU1 assembly. We solved the 8 
structure of SMU1 N-terminal domain in complex with RED or bound to one of the molecules 9 
identified to disrupt this complex. We show that these compounds inhibiting RED-SMU1 10 
interaction also decrease endogenous RED-SMU1 levels, inhibit viral mRNA splicing and 11 
viral multiplication, whilst preserving cell viability. Overall, our data demonstrate the potential 12 
of RED-SMU1 destabilizing molecules as a novel antiviral therapy, which could be active 13 
against a wide range of influenza viruses and be less prone to drug resistance.  14 
 15 
 16 
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 3 
Significance Statement   1 
 2 
Influenza virus is a serious threat to global public health and there is a critical need for 3 
innovative anti-influenza drugs. Two broad, non-exclusive approaches to inhibit viral 4 
replication are possible, either targeting directly viral proteins or targeting host proteins 5 
essential for the viral life cycle. Here we took the second approach, which is more likely to 6 
counter the problem of drug-resistant virus emergence. Focusing on an essential host 7 
partner of influenza viruses, the RED-SMU1 splicing complex, we performed a virtual 8 
structure-based drug screening.  We identified two synthetic molecules which interfere with 9 
RED-SMU1 complex assembly, inhibit the splicing of viral messenger RNAs, and show 10 
potential for the inhibition of influenza virus infections.  11 
\body  12 
 4 
Introduction 1 
The increasing incidence of drug-resistant pathogens calls for the development of novel 2 
therapeutic strategies. In recent years, the concept of host-directed therapies, which target 3 
host determinants essential for the infectious life cycle and/or pathogenesis rather than 4 
pathogens components, has been rapidly expanding (1, 2). Preclinical studies suggest they 5 
could show clinical safety while providing the advantage of broad spectrum efficacy and 6 
reduced antiviral resistance. A range of host-directed therapies for several bacterial and viral 7 
diseases, with different mechanisms of action, are currently in clinical trials (1, 2).  8 
Influenza A viruses (IAVs) are a leading cause of morbidity and mortality worldwide, as they 9 
are responsible for recurring annual epidemics, frequent epizootics, and occasional 10 
pandemics (3). The drugs currently licensed for treatment of influenza target viral 11 
components (the M2 ion channel, the neuraminidase and the polymerase) and they all lead 12 
to the emergence of resistance variants. The M2 inhibitors are no longer recommended for 13 
use since currently circulating human H3N2 and H1N1pdm09 viruses have become naturally 14 
resistant to these drugs (4). Although the frequency of resistance to neuraminidase inhibitors 15 
(NAIs) of currently circulating human IAVs remains low (around 0.5%) (5), large clusters of 16 
H1N1pmd09 viruses resistant to oseltamivir, the most widely used NAI, have been observed 17 
(6, 7). The former seasonal H1N1 IAVs had become globally oseltamivir-resistant during the 18 
2007-2008 season (8). Favipiravir, a purine nucleoside analog also known as T-705, is 19 
undergoing phase III trials in America and Europe and has been approved in Japan to treat 20 
pandemic influenza virus infections. In October 2018, FDA approved Xofluza, a selective 21 
inhibitor of the polymerase PA subunit, for the treatment of acute uncomplicated influenza. 22 
However, the first evidence for viral adaptation to favipiravir treatment in cell culture has 23 
been reported recently (9, 10), and the emergence of PA variants with a mutation conferring 24 
resistance to Xofluza was observed in 9.7% of treated patients in the Phase III trial  (11). In 25 
this context, novel anti-influenza drugs are actively being sought to efficiently fight IAVs, 26 
particularly with regard to pandemic preparedness (12, 13). Antivirals currently in late-phase 27 
clinical trials include monoclonal antibodies against the viral hemagglutinin or matrix protein 28 
 5 
(14, 15), a selective inhibitor of the polymerase PB2 subunit (16), and two compounds 1 
targeting host cell factors: nitaxozanide, which impairs trafficking and maturation of the viral 2 
hemagglutinin (HA) (17, 18); and DAS181, which enzymatically removes the membrane 3 
receptors required for IAV attachment to target cells (19, 20). Continuous progress on the 4 
identification of host factors involved in IAV life cycle provides a basis for the development of 5 
alternative host-directed antiviral drugs (21, 22). Following this approach we have 6 
characterized the structure of a human splicing factor, RED-SMU1, that is essential for IAV 7 
life cycle, and exploited the structural data to investigate this cellular factor as a potential 8 
target for IAV therapy.  9 
Infectious IAV particles contain eight ribonucleoprotein complexes (vRNPs), corresponding to 10 
a set of eight distinct viral genomic RNA (vRNA) segments encapsidated with nucleoproteins 11 
(NP) and associated with the heterotrimeric viral RNA-dependent RNA polymerase (FluPol) 12 
consisting of the PB1, PB2 and PA subunits (3). The viral genome has a limited size (about 13 
13.5 kb), but IAVs have evolved a variety of strategies to expand their coding capacity. Viral 14 
mRNAs are synthesized by the FluPol in the nucleus of infected cells. Although most of 15 
these are intronless, the M, NS and PB2 segments produce both unspliced mRNAs (M1, 16 
NS1, PB2) and spliced mRNAs (M2, NS2, PB2-S1). We previously showed that FluPol 17 
recruits a complex formed by the human splicing factors RED (78.9 kDa) and SMU1 (57.5 18 
kDa) by direct binding to RED (23). RED-SMU1 regulates the splicing of viral NS1 mRNA 19 
into the mRNA encoding the multifunctional and essential NS2/NEP protein. In cells depleted 20 
for RED or SMU1, the production of infectious influenza virions showed a 100-fold reduction 21 
(23), designating the RED-SMU1 complex as a promising IAV drug target.  22 
The RED and SMU1 factors are associated to the pre-catalytic spliceosome (24). They were 23 
found to jointly regulate the splicing of specific cellular pre-mRNAs, with a possible role in the 24 
selection of cryptic 5’ splice sites (25-27). As we and others have observed that RED and 25 
SMU1 directly bind (23, 26, 28) and stabilize each other (23, 26, 27), a significant proportion 26 
of functional RED-SMU1 complexes is likely to exist.  27 
 6 
Here we performed subdomain analysis of human RED and SMU1 proteins using cell-based 1 
interaction assays, and solved the crystal structure of a minimal RED-SMU1 complex at 3.0 2 
Å resolution. The structure shows similarities to the recently published RED and SMU1 3 
orthologs in Caenorhabditis elegans (ceRED and ceSMU1) (29) but reveals a more intricate 4 
RED-SMU1 interface. Based on our structural findings, we identified small molecules that 5 
target an a-helix-groove interface essential for RED-SMU1 interaction. Lastly, we provide 6 
supporting data to demonstrate the potential of such RED-SMU1 destabilizing molecules for 7 
the inhibition of IAV infections.  8 
  9 
 7 
Results  1 
 2 
Delineation of a minimal RED-SMU1 complex  3 
We previously found that the N-terminal domain of RED (residues 1 to 315) binds to SMU1 4 
as efficiently as the full-length RED protein (23). Using a split-luciferase based interaction 5 
assay, we further delineated a minimal human RED-SMU1 complex. Plasmids encoding 6 
various subdomains of RED tagged with the Gluc2 fragment of Gaussia princeps luciferase 7 
were co-transfected with plasmids for the expression of SMU1 or SMU1Nter (residues 1-196) 8 
fused to the trans-complementing Gaussia princeps luciferase Gluc1 fragment. The rationale 9 
for RED truncations shown in Fig. 1A was based on secondary structure and disorder 10 
predictions (SI Appendix, Fig. S1), with an iterative testing and design approach. As 11 
revealed by the relative luciferase activities measured in cell extracts, the RED[206-260] 12 
subdomain (named thereafter REDmid) retained the interaction with SMU1 (black bars) or 13 
SMU1Nter (grey bars) (Fig. 1A). The SMU1 interaction signals were almost 8-fold higher with 14 
REDmid than with the full-length RED (p<0.01), and were higher than with any longer 15 
truncated version of RED. Western blot analysis of the cell lysates used for luciferase assay 16 
showed that this higher interaction signal was not due to a higher level of expression of 17 
REDmid (Fig. 1B, black arrowhead) compared to other deletion mutants of RED or to the full-18 
length RED (open arrowhead). A likely explanation is that the short REDmid subdomain is 19 
more stable thermodynamically than the longer versions of RED and that it becomes more 20 
accessible upon removal of the adjacent polypeptides. For several other protein pairs, it was 21 
indeed previously shown that interactions are more easily detected when using isolated 22 
interacting subdomains or peptides (30). Notably, the RED[219-299] subdomain produced 23 
lower interaction signals compared to REDmid but also to the full-length RED protein, 24 
suggesting that residues 206 to 218 of RED are essential for the interaction with SMU1.  25 
 26 
  27 
 8 
The 3D structure of human REDmid-SMU1Nter reveals two molecular interfaces 1 
Based on our cell-based interaction results, we set up a co-expression strategy to produce 2 
and pull-down the human REDmid-SMU1Nter complex, using a hexa-histidine tag fused to the 3 
N-terminus of REDmid. The recombinant complex was crystallized and the structure solved by 4 
molecular replacement using the X-ray structure of the SMU1Nter alone without REDmid 5 
obtained earlier (SI Appendix, Fig. S2 and Table S1). The final model was built using the 6 
anomalous signal of a Se-met derivative dataset for an accurate sequence assignment. The 7 
asymmetric unit is composed of sixteen molecules: eight SMU1Nter molecules that assemble 8 
into four dimers, and eight REDmid molecules each one being associated with a SMU1Nter 9 
monomer. The X-ray structure reveals two distinct interfaces between SMU1Nter and REDmid 10 
(Fig. 2A). First, the region of REDmid corresponding to residues 235-257 disrupts the initial 11 
fold of the N-terminus of SMU1Nter to form a three-stranded antiparallel β-sheet, that is 12 
uniquely stabilized by main chain interactions (Interface I, Fig. 2B). Second, the helical 13 
region of REDmid (corresponding to residues 211-221) lies in a hydrophobic groove delimited 14 
by three continuous α-helices (α4 to α6) on the surface of SMU1Nter (Interface II, Fig. 2C). 15 
The structural results are consistent with the high and low interaction signals measured with 16 
the SMU1-RED[206-260] and SMU1-RED[219-299] combinations, respectively (Fig. 1A).  17 
The comparison of our human REDmid-SMU1Nter structure with the recently published 18 
structure of a C. elegans minimal RED-SMU1 complex ((29) and SI Appendix, Fig. S3) is 19 
discussed below. Importantly, the human structure suggests that SMU1 needs to form a 20 
dimer to assemble with RED, as Interface I extends across two distinct SMU1Nter monomers. 21 
In agreement with this observation, SEC-MALLS analysis on purified full-length SMU1 22 
protein showed that it is mostly dimeric (Fig. S4A), and treatment of A549 or HEK-293T cells 23 
with the cell-permeable crosslinking agent disuccinimidyl suberate (DSS) followed by 24 
western blotting revealed that the endogenous SMU1 protein forms dimers in live cells (Fig. 25 
S4B).  26 
 27 
28 
 9 
Mutational analysis provides a rationale for targeting the a-helix:groove interface 1 
To confirm our structural data and assess the druggability of the RED-SMU1 interface, we 2 
performed structure-based mutational analysis of the full-length RED and SMU1 proteins. 3 
Point mutations were introduced at interface I (Fig. 2B) or II (Fig. 2C and Fig. 3A-B). Split-4 
luciferase complementation assays were performed and expression levels of the mutants 5 
were assessed (Fig. 3C-H). Short deletions in the domains of SMU1 (D3-7) or RED (D237-6 
241 or D254-256) involved in interface I reduced the RED-SMU1 interaction signal up to 3-7 
fold (Fig. 3C, black bars). In the presence of SMU1 mutations targeting the interface II 8 
(D57A-E89A, L60D-I63D, L73D-Y77D, L84D-L87D) or the hinge between interface I and II 9 
(P157T-P158T), a 2- to 10-fold reduction of the interaction signal was also observed (Fig. 10 
3D). Notably, no cumulative effect was observed when deletions at interface I were 11 
combined with the SMU1 mutations D57A-E89A destabilizing interface II (Fig. 3C, grey 12 
bars), suggesting that both molecular interfaces are required to stabilize the RED-SMU1 13 
complex. RED mutants L212D, V216D and L220D targeting interface II showed a 2-fold 14 
reduction of the interaction signals with SMU1 or SMU1-D57Q (Fig. 3E). In contrast the 15 
RED-N215D and M219D mutations had little effect on the interaction with SMU1 (Fig. 3E), 16 
as expected from the 3D structure (Fig. 3A-B). Together, these results confirm our structural 17 
findings, demonstrate that a mere disruption of interface II a-helix:groove impairs the stability 18 
of the RED-SMU1 complex, and point to SMU1 D57, L60, I63, L73, Y77, L84, L87 and E89 19 
as key RED binding residues. 20 
 21 
Disrupting the RED-SMU1 complex: proof-of-principle by overexpressing REDmid  22 
Based on the data presented above, we reasonned that if overexpressed, the REDmid helical 23 
domain should efficiently compete with the full-length RED protein for binding to the surface 24 
groove on SMU1, and thereby disrupt the RED-SMU1 complex. As a control, we used a 25 
REDmid-V216D mutant, which accumulates at the same levels as REDmid but is strongly 26 
impaired for SMU1 binding. Of note, the effect of V216D mutation on SMU1 binding is much 27 
stronger in the context of REDmid (> 99% reduction) compared to the full-length RED (about 28 
 10 
50% reduction) (SI Appendix, Fig. S5A). Upon overexpression of the mCherry-REDmid 1 
fusion protein we observed a >2-fold reduction of the RED-SMU1 interaction signal, as 2 
measured with the split-luciferase complementation assay, while with the control mCherry-3 
REDmid-V216D mutant, no such reduction was observed (p<0.01, SI Appendix, Fig. S5B-C).  4 
We then assessed the effect of REDmid overexpression on the endogenous RED-SMU1 5 
complex. As there is evidence that RED and SMU1 stabilize each other (23, 26, 27), RED-6 
SMU1 disruption is expected to result in decreased steady-state levels of the proteins. We 7 
observed a decrease in endogenous cellular levels of RED when overexpressing REDmid, 8 
whereas empty vectors or REDmid-V216D had no effect (Fig. S5D, upper panel). However, 9 
SMU1 levels remained unchanged (Fig. S5D, middle panel). A likely interpretation is that the 10 
SMU1 protein complexed with REDmid remains stable, whereas the dissociated RED protein 11 
undergoes degradation.  12 
Next we monitored the effect of REDmid overexpression on the replication of a recombinant 13 
A/WSN/33 virus carrying a luciferase reporter gene (WSN-PB2-Nanoluc). The luciferase 14 
activity measured in cell lysates prepared at 24 hours post-infection (hpi), was lower in cells 15 
overexpressing REDmid compared to cells transfected with the empty pCI vector or 16 
overexpressing REDmid-V216D (Fig. S5E). On the contrary, there was no significant 17 
difference between cells transfected with the empty pCI vector and those overexpressing 18 
REDmid-V216D. Furthermore, splicing of the viral NS1 mRNA into NS2 mRNA, which is 19 
dependent upon RED-SMU1 (23), was reduced in REDmid-expressing cells compared to the 20 
REDmid-V216D control (Fig. S5F). Overall, our findings strengthen the rationale of targeting 21 
the RED-SMU1 a-helix:groove interface to inhibit IAV replication.  22 
 23 
In silico identification and evaluation of RED-SMU1 disrupting compounds 24 
We used the available structural information on the REDmid-SMU1Nter complex to perform 25 
molecular docking-based screening for compounds targeting the RED-binding groove at the 26 
surface of SMU1Nter. The virtual high-throughput screening (vHTS) was performed on a set of 27 
4,121 chemical compounds from our in-house chemical database (LCPBT-DB), comparable 28 
 11 
to the Prestwick or FDA-approved libraries in terms of chemical diversity (see SI Appendix). 1 
A flow chart for the vHTS and compound selection pipeline is represented in Fig. 4A. To 2 
ensure a time/precision ratio compatible with vHTS we used a protocol in which amino acid 3 
side chains of the protein are left flexible only around the binding site, and we tested 10 4 
random conformers for each ligands. The resulting poses were ranked according to their 5 
docking scores, as described in the Methods section. The poses with the highest docking 6 
scores were further filtered to select for compounds that are predicted to bind at least 4 of the 7 
8 SMU1 residues required for efficient binding to RED: D57, L60, I63, L73, Y77, L84, L87, 8 
E89 (Fig. 4B and Fig. 3D). A total of 37 compounds fulfilled both criteria, and a subset of 16 9 
molecules with representative chemical scaffolds were further evaluated.     10 
Among these, 14 showed no or only limited cytotoxicity at 60 µM, and were further tested at 11 
the same concentration in cell-based assays for the inhibition of RED-SMU1 interaction and 12 
IAV replication. Compounds inhibiting RED-SMU1 interaction by more than 20%, and IAV 13 
replication by more than 80% were selected for further evaluation. In total, three compounds 14 
showed promising inhibitory effect in both assays (Fig. 4A). Of these, one molecule, LSP641 15 
(Fig. 4C), was successfully co-crystallised with the purified recombinant SMU1Nter domain. 16 
Structural data showed that LSP641 locates in the hydrophobic RED binding pocket of SMU1 17 
as expected (Fig. 4D) and is engaged in several molecular interactions with SMU1 (Fig. 4E). 18 
The 2-amino-pyrimidine group present in LSP641 forms key hydrogen bounds with Q61 and 19 
Q64, whereas the urea group forms a hydrogen bond with Y77. In the apolar region of 20 
SMU1, D57, L60 and L96 are involved in Pi-Pi or s-Pi interactions, in particular with the 21 
pyridopyrimidine scaffold of LSP641. Furthermore, W56, I63, L84 and A92 form hydrophobic 22 
interactions with LSP641. Remarkably, the LSP641 molecule interacts with D57, L60, I63, 23 
Y77 and L84, i.e. 5 of the 8 residues shown earlier to be involved in RED-SMU1 interaction, 24 
to account for the inhibition of this protein-protein interaction. 25 
Guided by the SMU1Nter:LSP641 co-structure, we selected 27 LSP641-related compounds 26 
and we filtered them through a second evaluation round (Fig. 4A), which led to the selection 27 
of LSP61 (31) (Fig. 4C and 4F). Unfortunately, we were unable to co-crystallize LSP61 with 28 
 12 
SMU1 Nter. This different behavior of LSP61 compared to LSP641 might be related to the 1 
absence/presence of stacking interactions in the co-crystal. However, in silico molecular 2 
docking supported binding interactions similar to LSP641 (Fig. 4G). Hydrogen bonds with 3 
Q64 and Y77 are conserved, as well as Pi- or s-Pi-interactions with D57 and L60, and 4 
hydrophobic interactions with W56 and L84. Q61 is involved in Pi-interactions, whereas V41, 5 
V80 and L96 are forming novel hydrophobic interactions. Most importantly, the 6 
benzylpiperidine group of LSP641 that is not binding SMU1 in the crystal structure (Fig. 4D-7 
E), is replaced in LSP61 by an alkyl chain which interacts with A62 and V41 in a neighboring 8 
hydrophobic pocket of SMU1 and therefore optimizes molecular recognition (Fig. 4F-G). This 9 
led us to select LSP61 to conduct further investigations, in parallel with LSP641.   10 
LSP61 and LSP641 were compared in the RED-SMU1 interaction assay across the 0.23 to 11 
60 µM concentration range. The EC50 (half-maximal effective concentration) was estimated 12 
to be 15 µM for LSP61 ; LSP641 showed a milder effect resulting in a 40% inhibition at 60 13 
µM, compared to 90% with LSP61, and a plateauing curve (Fig. 5A). When a similar 14 
FOS:JUN interaction assay was used as a specificity control, none of the two compounds 15 
showed any significant effect (Fig. 5B). The Kd of the SMU1Nter-LSP61 complex could not be 16 
determined, most likely due to the low solubility of LSP61 (logP=4.8). The effect of LSP61 on 17 
the endogenous RED-SMU1 complex was assessed using the steady-state levels of RED 18 
and SMU1 as a proxy. Expression levels of both proteins decreased when treating cells with 19 
15, 30 and 60 µM LSP61 (Fig. 5C). At these concentrations, no cytotoxicity but some 20 
cytostatic effect was observed as assessed by the steady levels of ATP measured in culture 21 
wells (a proxy for cell count) upon 24 and 48 hours of incubation with LSP61 (Fig. 5D) and 22 
the observation of cell monolayers by bright field miscroscopy (SI Appendix, Fig. S6).  23 
 24 
LSP61 inhibits IAV replication  25 
Finally we assessed the ability of LSP61 to inhibit IAV replication. We first used the WSN-26 
PB2-Nanoluc virus, in parallel with a recombinant human Respiratory Syncytial Virus (RSV) 27 
expressing Firefly luciferase as a specificity control (RSV replicates in the cytoplasm with no 28 
 13 
direct involvement of the nuclear splicing machinery postulated). After viral adsorption to 1 
A549 cells, the LSP61 or LSP641 compounds were added to the cells across the 7.5 - 60 µM 2 
concentration range, and the luciferase activities were determined at 24 hpi. The RSV-Firefly 3 
signals showed only moderate reductions (Fig. 6A, grey bars). In contrast the WSN-Nanoluc 4 
signals showed a significant, dose-dependent reduction, more pronounced for LSP61 (25-5 
fold at 60 µM, p<0.0001) compared to LSP641 (6-fold at 60 µM, p<0.005) (Fig. 6A, black 6 
bars). Growth kinetics were performed with wild-type IAVs (the WSN virus and 7 
representatives of H1N1pdm09 and H3N2 circulating human IAVs) in the presence of 60 µM 8 
LSP61 and the supernatants were titrated by plaque assay. Because the H1N1pdm09 and 9 
H3N2 isolates grew poorly on A549 cells, canine MDCK-SIAT cells (32) were used in these 10 
experiments. In the presence of LSP61 the production of infectious particles showed a 10- to 11 
100-fold reduction at 24 and 48 hpi (Fig. 6B). In comparison, on A549 cells, the production of 12 
WSN infectious particles was reduced about 1000-, 100- and 10-fold at 24, 48 and 72 hpi, 13 
respectively (Fig. 6C). In MDCK-SIAT cells, canine Mx proteins lack anti-influenza activity, 14 
which limits the establishment of a strong interferon-induced antiviral state and favors a very 15 
efficient replication of influenza viruses (33). This particular feature of MDCK-SIAT cells likely 16 
accounts for the fact that a strong inhibition with the LSP61 compound was more difficult to 17 
achieve compared to in A549 cells.  18 
In WSN-infected cells, the LSP641 and LSP61 compounds inhibited the splicing of the viral 19 
NS1 mRNA into NS2 mRNA at 60 µM concentration. Indeed, the NS2 to NS1 mRNA ratio 20 
was reduced by 30% with LSP641, and 50% with LSP61 (Fig. 6D), which is comparable to 21 
previous results obtained when either RED or SMU1 was knocked-down in infected cells 22 
(23). In contrast LSP641 and LSP61 did not inhibit the splicing of the viral M1 mRNAs (Fig. 23 
S7A), in agreement with our previous findings that M1 mRNA splicing is little affected by 24 
RED or SMU1 silencing compared to NS1 mRNA splicing (23). Likewise, PB2 mRNA 25 
splicing, whose role in viral infection remains unclear (34), is not affected by 60 µM LSP641 26 
or LSP61 (Fig. S7B). The specificity of LSP641 and LSP61 towards the splicing of NS1 27 
mRNA, taken together with our findings that both compounds inhibit RED-SMU1 interaction 28 
 14 
(Fig. 5A) and IAV replication (Fig. 6A), with the observed effects being consistently more 1 
pronounced for LSP61, strongly argue for their antiviral effect being due to disruption of the 2 
RED-SMU1 complex.  3 
 4 
  5 
 15 
Discussion  1 
We have determined the crystal structure of the interacting human SMU1 N-terminal region 2 
(SMU1Nter) and RED central region (REDmid). As expected from the high conservation of 3 
these two protein subdomains, the observed structure shows similarity to the one reported 4 
for C. elegans (29). In both structures SMU1Nter assembles into a dimer through inter-5 
molecular contacts between LisH motifs (SI Appendix, Fig. S2). Interestingly our structure 6 
reveals a more intricate SMU1-RED interaction with two binding interfaces, including a ß-7 
sheet:ß-sheet interface (not present in the C. elegans structure) in addition to an a-8 
helix:groove (SI Appendix, Fig. S3). Unlike Ulrich et al. who assembled complexes from 9 
purified RED and SMU1 subdomains produced separately in E. coli (29), we chose a co-10 
expression strategy which allowed us to first delineate in HEK-293T cells and then to co-11 
purify from E. coli a very stable REDmid-SMU1Nter complex. RED and SMU1 are part of the 12 
spliceosomal pre-catalytic B complex, whose molecular architecture was very recently 13 
elucidated by cryo-EM (35). Fitting of our atomic structure of REDmid-SMU1Nter enabled us to 14 
refine the cryo-EM 3D model by applying the conformational constraint imposed by the newly 15 
revealed ß-sheet:ß-sheet interface between REDmid and SMU1Nter. The model (SI Appendix, 16 
Fig. S8) highlights a major structural role for RED, as it is positioned at the interface of the 17 
SMU1 LisH motif-based dimerization domain and the SF3B1 core spliceosomal factor. This 18 
pivotal position could contribute to a stabilization of the B complex structure during the early 19 
stages of spliceosome assembly that precede catalytic activation.  20 
Based on our human REDmid-SMU1Nter structure, we designed pilot experiments and in silico 21 
screening which led to the identification of two inhibitors, LSP641 and LSP61; they disrupt 22 
the RED-SMU1 interaction, reduce RED-SMU1 endogenous levels, inhibit IAV NS1 mRNA 23 
splicing and decrease the production of infectious IAV particles. These findings add to a 24 
growing list of more than 40 protein-protein interactions that have been successfully targeted 25 
with small drug-like molecules, at least in vitro (36, 37).  Several inhibitors have entered 26 
clinical trials, including inhibitors of the p53-MDM2 interaction (38) and inhibitors of the 27 
interaction between the HIV-1 integrase and its cofactor LEDGF (39). Prospects for 28 
 16 
developing inhibitors seem to be higher for protein-protein interactions in which residues 1 
critical for the interaction are concentrated in small binding pockets, as is the case for the a-2 
helix:groove interface between REDmid and SMU1Nter. In the recent years much progress has 3 
also been made to enhance the therapeutic potential of short cell-permeable peptides as an 4 
alternative to conventional therapeutic small molecules (40). In principle a peptide 5 
corresponding to the short RED[211-222] a-helix could be considered as a potential inhibitor 6 
of RED-SMU1 interaction. However the strong hydrophobicity of this a-helix is likely to 7 
prevent its solubilisation and to preclude such a strategy from being successful.  8 
The potential toxicity associated with host-directed therapy also needs to be carefully 9 
evaluated. Cultured A549 cells treated with RED-SMU1 targeting compounds LSP461 and 10 
LSP61 (this study), or treated with RED-SMU1 targeting siRNAs with a depletion efficiency of 11 
90% (23) did not show cell death. Consistently, RED or SMU1 knock-outs in C. elegans or A. 12 
thaliana are viable (25, 27). However, a cytostatic effect of compound LSP61 was observed, 13 
as evidenced by bright field imaging showing a lower density of the cell layer in the absence 14 
of dead cells, and ATP quantification supporting a slower accumulation of metabolically 15 
active cells in culture wells. This observation is in agreement with previous reports showing 16 
that RED and SMU1 jointly regulate alternative splicing of a subset of pre-mRNAs involved in 17 
development, apoptosis and cell survival (25-27, 41, 42). The transcriptomic profiling of cells 18 
treated with compound LSP61 (or depleted for RED-SMU1 as a reference) will provide a 19 
means to investigate how LSP61 affects the expression and splicing of cellular genes, and  20 
detect potential adverse effects to guide further drug development (43). Beyond their splicing 21 
function, RED and SMU1 are associated with the mitotic spindle (44) and chromatin (45), 22 
respectively, and are involved in the control of cell division (44, 46). The dual function of 23 
RED-SMU1 raises the question whether our observed anti-viral effect of compounds LSP461 24 
and LSP61 could be related not only to inhibition of viral mRNA splicing (as indicated by a 25 
reduced NS2 to NS1 mRNA ratio upon treatment) but also cell cycle arrest. Although this 26 
possibility cannot be formally excluded, it seems unlikely as IAV infection per se has been 27 
shown to induce G0/G1 cell cycle arrest through inhibition of the RhoA/pRb signaling 28 
 17 
pathway (47) and down-regulation of cyclin D3 levels (48) in cultured cells. Besides, the 1 
tissue naturally targeted by IAVs, i.e. the airway epithelium, is essentially quiescent in 2 
healthy hosts (49). However, mitogenic stimulation through intra-tracheal administration of 3 
the keratinocyte growth factor in mice was found to induce the proliferation of alveolar type II 4 
cells (normally quiescent by more than 99%), and this increased their susceptibility to IAV 5 
infection (50). The authors suggest that the enhanced mortality due to influenza in infants or 6 
cigarette smokers could be related to a higher fraction of proliferating alveolar type II cells in 7 
these patients. Under this hypothesis, compounds targeting RED-SMU1 might show a 8 
double effect of inhibiting IAV replication through splicing modulation, and limiting the 9 
intrapulmonary spread of IAV infection through cytostatic activity. 10 
Over the last two decades a growing number of small molecules that inhibit the spliceosome 11 
assembly or function have been identified, but many of them have yet to be characterized 12 
regarding their target and mechanism of action. The most documented are SF3B1 inhibitors 13 
of the spliceostatins, pladienolides and sudemycins families (51-53). Although these drugs 14 
target a core splicing factor, there is evidence for a certain degree of selectivity. SF3B1 15 
inhibitors affect splicing of pre-mRNAs associated with cell cycle regulation and apoptosis, 16 
and inhibit growth of cultured cancer cell lines at nM concentrations while cells derived from 17 
normal tissues are less sensitive (for a review see (54, 55)). Preclinical studies have 18 
suggested that splicing modulation by SF3B1 inhibitors can be well tolerated in vivo and 19 
show potential for the treatment of several types of cancers (56-58). Taking these data into 20 
account, together with the absence of observed cytotoxicity of LSP641 and LSP61 in our 21 
experiments, and with the fact that a topical and short time course treatment can be 22 
considered in the case of acute IAV infections, compounds targeting the RED-SMU1 23 
complex can reasonably be expected to show clinical safety and efficacy in influenza 24 
therapy. Our SMU1Nter-LSP641 co-structure provides a valuable basis for chemical 25 
optimization in order to select compounds with improved activity, specificity and 26 
pharmacological properties, which can be tested in vivo in preclinical animal models for IAV 27 
infection. Such optimized RED-SMU1 disrupting compounds could be active against a wide 28 
 18 
range of IAVs, and be less likely to select for resistance mutants. Interestingly, RED and 1 
SMU1 were identified as hits in two high-throughput screens looking for cellular factors 2 
involved in HIV-1 life cycle (59, 60). SMU1 was also found to be associated to the E6 protein 3 
of the high-risk HPV18 human papillomavirus (61). Therefore RED-SMU1 disrupting 4 
compounds might not only be active against IAVs but against a wider range of viruses that 5 
make use of the RED-SMU1 splicing complex. Besides potential applications as antivirals, 6 
our small molecule inhibitors might also serve as tools to dissect the early stages of 7 
spliceosome assembly, and lead to potential applications as anti-cancer agents (54, 62, 63).  8 
  9 
19 
Materials and Methods 1 
 2 
Cells, viruses, plasmids and reagents. See SI Appendix for detailed information 3 
 4 
In cellulo split luciferase-based interaction assays 5 
The split-luciferase protein complementation assays were performed as described in (64). 6 
Briefly, HEK-293T or A549 cells were seeded in 96-well white opaque plates (Greiner Bio-7 
One) and co-transfected with 100 ng of each indicated pGluc1-P1 and pGluc2-P2 plasmids, 8 
where P1 and P2 represent proteins or protein subdomains of interest. The polyethylenimine 9 
PEI (Polysciences Inc) and JetPRIME (Polyplus Transfection) transfection reagents were 10 
used with HEK-293T and A549 cells, respectively. Normalized luciferase values were 11 
determined as described in (23, 64). At 24 h post-transfection, the luciferase enzymatic 12 
activities were measured using the Renilla luciferase assay system (Promega) and a 13 
Berthold Centro XS luminometer. When cell-based interaction assays were performed for 14 
compound screening, control HEK-293T cells transfected with a full-length Gaussia 15 
luciferase expression plasmid were incubated in parallel with tested compounds or DMSO 16 
alone. The split-luciferase values were normalized with respect to control full-length 17 
luciferase signals. 18 
 19 
Protein expression in E. coli and protein purification 20 
The pETM11-SMU1Nter plasmid was transformed in E. coli BL21-CodonPlus (Agilent). 21 
Cultures were grown at 37°C in LB containing kanamycin (30 µg/mL) and chloramphenicol 22 
(34 µg/mL). When the OD600nm reached 0.6-0.8, the cultures were cooled down to 18°C and 23 
expression induced with 0.3 mM isopropyl-thiogalactopyranose (IPTG). The cultures were 24 
incubated overnight at 18°C before centrifugation. For the SMU1Nter-REDmid complex, a co-25 
expression strategy was set up. The pETM11-REDmid plasmid was transformed in E. coli 26 
BL21-RIL-SMU1Nter competent cells and expression performed using the protocol described 27 
above.Cell pellets were resuspended in lysis buffer (50 mM Hepes pH7.5, 150-500 mM 28 
 20 
NaCl, 1 mM β-mercaptoethanol (βme)), and sonicated. After centrifugation, the supernatant 1 
was complemented with imidazole to reach 25mM and loaded on a nickel affinity column 2 
(NiNTA, GIAGEN). The resin was washed with a high salt buffer (50 mM Hepes pH7.5, 1 M 3 
NaCl,1 mM βme). The recombinant proteins were eluted with elution buffer (50 mM Hepes 4 
pH7.5, 1 M NaCl, 1 mM βme, 300mM imidazole). Protein were dialyzed with TEV protease 5 
overnight against the buffer without imidazole, loaded on a second NiNTA column, 6 
concentrated and loaded on a size exclusion column, a HiLoad 16/600 Superdex 75 (GE 7 
Healthcare) for SMU1Nter or a Superdex 200 Increase 10/300GL (GE Healthcare) for the 8 
SMU1Nter-REDmid complex. Fractions of interest were concentrated between 5 and 15 mg/mL. 9 
 10 
Structure determination 11 
For SMU1Nter, the crystals (native and Se-Met derivative) were obtained in 0.1 M Bis-Tris 12 
pH5.5, 16-20 % PEG 10K, 0.1 M ammonium acetate and cryoprotected in the same solution 13 
+ 30 % glycerol. Data were processed with the XDS package (65). For experimental phasing 14 
of SMU1Nter a highly redundant single wavelength anomalous dataset of a Se-Methionine 15 
(Se-Met) derived crystal was collected to 2.1 Å resolution at the peak of the Se-Met signal, 16 
as measured by X-ray fluorescence, on ID29 (66) at the European Synchrotron Radiation 17 
Facility (ESRF). For structural solution 8 Se-Met sites were located on the basis of their 18 
anomalous differences using SHELXC/D/E (67). These sites were subsequently refined and 19 
experimental phases were calculated using the single anomalous dispersion (SAD) 20 
procedure in SHARP (68). These phases were further improved by density modification 21 
followed by model building with the Buccaneer software (69). Model building and refinement 22 
were performed using CCP4i suite program for crystallography (PHASER, ARP/wARP, 23 
REFMAC5, COOT) (70-74). 24 
For the REDmid-SMU1Nter complex, the crystals (native and Se-Met derivative) were obtained 25 
in 0.1 M Hepes pH 7.0-7.5, 8-10 % PEG 8K and cryoprotected in the same solution + 30 % 26 
glycerol. Data were processed with XDS and the structure was solved by molecular 27 
replacement using the native SMU1Nter structure. The model was built using the anomalous 28 
 21 
signal of a Se-met derivative dataset for an accurate side chains attribution, and the final 1 
refinement was performed using the software mentioned above.  2 
For the SMU1Nter + LSP641 complex, a mother solution of LSP641 was prepared at 125 mM 3 
in DMSO. The co-crystals of SMU1Nter (10 mg/mL) + 2.5 mM LSP641 were obtained in 0.1 M 4 
Bis-Tris pH 6, 16-20 % PEG 10K, 0.2 M ammonium acetate and cryoprotected in the same 5 
solution + 30 % glycerol. Data collection, processing and model building were performed as 6 
described above. 7 
 8 
In silico screening  9 
Docking experiments were performed using the LibDock protocol, as implemented in 10 
Discovery Studio (Discovery Studio Modeling Environment, release 4.5; Dassault Systemes 11 
BIOVIA: San Diego, 2015), an interface to the LibDock program developed by Diller and 12 
Merz (75). LibDock uses protein site features referred to as HotSpots that fall into two 13 
categories: polar and apolar HotSpots. The receptor HotSpot file was calculated prior to the 14 
docking procedure. Random ligand conformations were generated from the initial ligand 15 
structure through high-temperature molecular dynamics using the BEST algorithm before 16 
docking. The rigid ligand poses were placed into the active site and HotSpots were matched 17 
as triplets. The poses were pruned and a final optimization step was performed before the 18 
poses were scored. Ligand hydrogens, which were removed during the docking process, 19 
were added back to the ligand poses and optimized by minimization. The poses with the 20 
highest LibDock scores were retained and clustered according to their binding mode.  21 
 22 
RNA extraction and reverse transcription-quantitative PCR 23 
Total RNA and poly(A)+ RNAs were extracted subsequently using the RNeasy Mini Kit 24 
(Qiagen) and Oligotex mRNA Mini kit (Qiagen) following the manufacturer’s protocol. 25 
Reverse transcription (RT) was performed on 5-10 ng of total mRNA (or poly(A)+ RNA 26 
equivalent) using the Maxima First Strand cDNA Synthesis Kit (Thermo Scientific). 27 
Quantitative real-time PCR was performed on 2 μL of a 1/10 dilution of the RT reaction using 28 
 22 
the Luminaris Color Probe qPCR Master Mix (Thermo Scientific) and a Light Cycler 480 1 
(Roche). The levels of NS1/NS2 and M1/M2 mRNAs were determined and normalized with 2 
respect to GAPDH mRNA levels  using the protocol described in (23). The levels of 3 
PB2/PB2-S1 mRNAs were determined by semi-quantitative RT-PCR as described in (34).   4 
 5 
Data Availability Statement 6 
Structure coordinates and diffraction data are available on the Protein Data Bank 7 
(http://www.pdb.org) under accession codes PDB: 6Q8F (SMU1Nter), 6Q8I (REDmid-8 
SMU1Nter), and 6Q8J (SMU1Nter-LSP641). 9 
 10 
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Figure legends 1 
 2 
Figure 1. RED-SMU1 interaction mapping using a cell-based assay.  3 
The Gaussia princeps luciferase-based complementation assay was performed as described 4 
in the Methods section. Gluc2-fused RED full-length (RED) or indicated subdomains were 5 
coexpressed with Gluc1-fused SMU1 full-length (SMU1) or SMU1[1-196] (SMU1Nter) by 6 
transient transfection in HEK-293T cells. A. The normalized luciferase activities are 7 
expressed as percentages relative to the activity measured with full-length RED and SMU1 8 
proteins. The data shown are the mean +/- SD of three independent experiments in 9 
triplicates. Black and grey bars represent luciferase activities measured in the presence of 10 
SMU1 and SMU1Nter, respectively. ** : p<0.01 (parametric unpaired t-test). On the schematic 11 
diagram of RED its characteristic stretch of repeated arginine, glutamic acid and aspartic 12 
acid residues is represented by a hatched box. The dotted line highlights the interaction 13 
between the two components of the minimal SMU1Nter-REDmid complex. B. Cell lysates used 14 
to determine luciferase activities in A were subsequently analysed by western blot using 15 
antibodies specific for Gaussia princeps luciferase (Gluc, upper panel) and Glyceraldehyde 16 
phosphate deshydrogenase (GAPDH, lower panel). White arrowhead: Gluc1-SMU1; Open 17 
arrowhead: Gluc2-RED; Black arrowhead: Gluc2-RED[206-260], renamed Glu2-REDmid in the 18 
text.  19 
 20 
Figure 2: Crystal structure of the recombinant human REDmid-SMU1Nter complex.  21 
A. Global view of the complex. The REDmid and SMU1Nter proteins are coloured in red and 22 
yellow respectively. One monomer of SMU1Nter is shown as a ribbon diagram and the second 23 
as a surface representation. B. Close-up view of the mixed ß-sheet formed by the interaction 24 
of RED[235-257] with the N-terminal ß-strand of a SMU1Nter monomer, and stabilized by the 25 
C-terminal surface of the other dimer partner SMU1Nter molecule. C. Details of the second 26 
interface corresponding to the α-helical part of REDmid inserted into a hydrophobic groove at 27 
the surface of SMU1Nter. The images were generated using PyMOL (76).  28 
 29 
Figure 3. Structure-based analysis of the RED-SMU1 interface.  1 
A. Schematic representation of Interface II. On the helical weel representation of RED 2 
(residues 213 to 222), aliphatic residues (in a grey frame) are concentrated at the RED-3 
SMU1 interface. The  polar residues (in blue) are exclusively located on the opposite side. B. 4 
Location of SMU1 and RED residues (coloured in green and purple, respectively) involved in 5 
interactions at interface II and subjected to mutagenesis experiments shown in panels C to 6 
H. C-E. Luciferase-based complementation assays were performed as described in the 7 
Methods section with the indicated combinations of wild-type (wt) or mutant proteins. The 8 
normalized luciferase activities are expressed as percentages relative to the activity 9 
measured in the presence of the wt SMU1 and RED proteins. The data shown are the mean 10 
+/- SD of three independent experiments in triplicates, except when SMU1-D57A-E89A was 11 
tested in (C): two independent experiments. ** p<0.01, *** p<0.001 unpaired t-test. F. The 12 
indicated combinations of wt or mutant SMU1 and RED proteins, fused to the Strep-tag, were 13 
transiently co-expressed in HEK-293T cells. Cell lysates were analysed by western blot, 14 
using HRP-conjugated Streptactin (lower panel). GAPDH (upper panel) was used as a 15 
loading control. G-H. Cell lysates used to determine luciferase activities in C and D were 16 
subsequently analysed by western blot, using antibodies specific for Gluc (lower panel) and 17 
an anti-GAPDH antibody (upper panel). 18 
 19 
Figure 4. SMU1Nter binding to compounds LSP641 and LSP61.  20 
A. Flow chart of in silico screening and compound evaluation. The indicated assays were 21 
performed as described in the Methods section, in the presence of compounds at 60 µM or 22 
DMSO. The Venn diagrams show the number of selected compounds. The cut-off applied 23 
are indicated in italics (cell viability assay: < 2-fold reduction in CellTiter-Glo signal after 36h 24 
incubation with the compound compared to DMSO; RED-SMU1 and IAV replication assays: 25 
≥ 20%  and ≥ 80% reduction in Gaussia luciferase and Nanoluc signal, respectively, in the 26 
presence of the compound compared to DMSO). B. SMU1Nter residues required for efficient 27 
binding to RED (coloured in green) and used for filtering of the docking poses. C. Chemical 28 
 30 
structures of compounds LSP641 and LSP61. D. Co-crystal structure of LSP641 in complex 1 
with SMU1Nter. The LSP641 binding pocket is coloured according to hydrophobicity (blue: 2 
hydrophilic, red: hydrophobic). E. Residues of SMU1 involved in LSP641 binding. Green: key 3 
residues for RED binding which also interact with LSP641. Orange: other residues which 4 
strongly interact with LSP641 in the co-crystal structure. F. Representative pose of LSP61 5 
upon in silico docking on SMUNter. The LSP61 binding pocket is coloured according to 6 
hydrophobicity (blue: hydrophilic, red: hydrophobic). G. Residues of SMU1 predictively 7 
involved in LSP61 binding. Green: key residues for RED binding which also interact with 8 
LSP61 upon molecular docking. Orange: other residues which strongly interact with LSP61 9 
upon molecular docking. 10 
 11 
Figure 5. Evaluation of compound LSP61 for RED-SMU1 destabilisation.  12 
A. RED-SMU1 interaction assay. The split-luciferase assay was performed as described in 13 
the Methods section. At 8 hours post-transfection (hpt), the A549 cells were incubated with 14 
the relevant compounds at the concentrations indicated. The normalized luciferase units 15 
measured at 24 hpt are expressed as percentages relative to the DMSO-treated control. The 16 
data shown are the mean +/- SD of three independent experiments in triplicates. ** p<0.005 17 
(parametric unpaired t-test). B. The split luciferase interaction assay was performed as in A, 18 
using Gluc1-FOS and Gluc2-JUN plasmids. The data shown are the mean +/- SD of two 19 
independent experiments in triplicates. C. Effect on the steady-state levels of the 20 
endogenous RED and SMU1 proteins. A549 cells were incubated with the indicated 21 
concentrations of LSP61 (+) or with DMSO (-) for 24h. Total cell extracts were analyzed by 22 
western blot, using antibodies specific for RED, SMU1 and GAPDH. D. Cell viability assay. 23 
A549 cells were incubated with the indicated concentrations of LSP61 or with DMSO. ATP 24 
levels, which reflect the number of viable cells, were determined using the CellTiter-Glo kit 25 
(Promega) at the onset of the experiment (T0), and following 24 or 48 hours of incubation 26 
(T24, T48). The data shown are the mean of luciferase units +/- SD of two independent 27 
experiments in duplicates.  28 
 31 
Figure 6. Evaluation of compound LSP61 for anti-IAV activity.  1 
A. Effect on IAV replication. A549 cells were infected with the WSN-Nanoluc or RSV-Firefly 2 
virus (0.001 and 0.01 PFU/cell, respectively) and incubated with LSP641 or LSP61 at the 3 
indicated concentrations, or with DMSO. The luciferase units measured at 24 hpi are 4 
expressed as percentages relative to DMSO-treated control. The data shown are the mean 5 
+/- SD of three (WSN-Nanoluc) or two (RSV-luc) independent experiments in triplicates. 6 
**p<0.005, ***p<0.0001 (parametric paired t-test). B-C. Effect on the production of infectious 7 
particles. MDCK-SIAT (B) or A549 cells (C) were infected with the WSN, H1N1pdm09 or 8 
H3N2 viruses as indicated, and incubated with 60 µM of LSP61 or with DMSO. At 24, 48, 9 
and 72 hpi, the supernatants were collected and viral titers determined by plaque assay. The 10 
data are expressed as mean +/- SD of three independent experiments (except for the 24 hpi 11 
time-point in C and D : two independent experiments), each in triplicates that were pooled for 12 
titration. * p<0.05, ** p<0.01, *** p<0.001, parametric paired t-test. D. Effect on NS1 mRNA 13 
splicing. A549 cells were infected with the WSN-wt virus (5 PFU/cell), and incubated with 60 14 
µM of LSP641 or LSP61, or with DMSO. After 6 h incubation, polyA+ RNA were extracted 15 
and the levels of NS2 and NS1 mRNAs were analyzed by quantitative real-time PCR and 16 
normalized with respect to GAPDH mRNA levels. The NS2/NS1 mRNA ratios shown are the 17 
mean +/- SD of three independent experiments in duplicates. p=0.01, parametric paired t-18 
test. 19 
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